Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BMS-986165 in Hepatic Impairment
NCT03890809Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of deucravacitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 9 days, Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration at 9 days and 1 more. Started Feb 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03890809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890809.